In the United States, after removing the weight loss drug Zepbound from its list of covered medications last year, CVS Caremark has announced plans to reinstate coverage effective October 1, 2026, following significant backlash from patients. This decision came after many patients reported better results using Zepbound compared to the alternative, Wegovy, which forced some to switch when CVS discontinued Zepbound. The backlash included a class-action lawsuit filed in September 2025 in response to the removal, highlighting the challenges patients faced in accessing preferred treatments. Patients expressed frustration over the high out-of-pocket costs associated with Zepbound. With a monthly list price of $1,086, personal expenses could still run into hundreds of dollars even after considering cash discounts from Eli Lilly, the drug manufacturer. When Zepbound is covered again, some patients with private insurance will benefit from copays as low as $25, demonstrating how restorative actions can address patient needs. Alongside Zepbound's return, a new weight loss pill called Foundayo will also be added to CVS Caremark’s formulary. This reinstatement of Zepbound to CVS's standard formulary potentially impacts around 25 million to 30 million individuals, although it does not guarantee that every insurance plan will cover the drug, as final coverage decisions are typically made by employers. Nonetheless, having Zepbound on the formulary increases the likelihood of broader insurance coverage, helping to relieve some of the previous burdens on patients. CVS Caremark's decision aligns with similar policies from other major pharmacy benefit managers, such as Express Scripts and Optum Rx, which already cover Zepbound. This illustrates a shifting landscape in pharmaceutical coverage that increasingly takes patient feedback into account as a driver of policy changes. Furthermore, as the landscape of weight-loss medications evolves, the attention brought to patient needs and responses can lead to enhanced coverage practices that better support individual health outcomes.